- 関
- bucladesine、db-cAMP、dibutyryl cyclic AMP
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2014/09/25 12:00:25」(JST)
[Wiki en表示]
Bucladesine
|
Systematic (IUPAC) name |
sodium (3aR,4R,6R,6aR)-4-(6-butanamido-9H-purin-9-yl)-6-[(butanoyloxy)methyl]-2-oxo-tetrahydro-2H-1,3,5,2λ5-furo[3,4-d][1,3,2]dioxaphosphol-2-olate |
Clinical data |
AHFS/Drugs.com |
International Drug Names |
Legal status |
?
|
Identifiers |
CAS number |
362-74-3 Y |
ATC code |
C01CE04 |
PubChem |
CID 28177 |
ChemSpider |
9306 Y |
UNII |
63X7MBT2LQ Y |
ChEBI |
CHEBI:50095 Y |
ChEMBL |
CHEMBL485980 Y |
Synonyms |
• Dibutyryl cyclic adenosine monophosphate
• (N6,2'-O-dibutyryl)-adenosine-3',5'-mono-phosphate
• Dibutyryl cAMP
• DcAMP
• DBcAMP |
Chemical data |
Formula |
C18H23N5NaO8P |
Mol. mass |
491.368 g/mol |
SMILES
- O=C(Nc4ncnc1c4ncn1[C@@H]2O[C@@H]3COP(=O)(O[C@H]3[C@H]2OC(=O)CCC)O)CCC
|
InChI
-
InChI=1S/C18H24N5O8P/c1-3-5-11(24)22-16-13-17(20-8-19-16)23(9-21-13)18-15(30-12(25)6-4-2)14-10(29-18)7-28-32(26,27)31-14/h8-10,14-15,18H,3-7H2,1-2H3,(H,26,27)(H,19,20,22,24)/t10-,14-,15-,18-/m1/s1 Y
Key:CJGYSWNGNKCJSB-YVLZZHOMSA-N Y
|
Y (what is this?) (verify) |
Bucladesine is a cyclic nucleotide derivative which mimics the action of endogenous cAMP and is a phosphodiesterase inhibitor.
Bucladesine is a cell permeable cAMP analog. The compound is used in a wide variety of research applications because it mimics cAMP and can induce normal physiological responses when added to cells in experimental conditions. cAMP is only able to elicit minimal responses in these situations.
The neurite outgrowth instigated by bucladesine in cell cultures has been shown to be enhanced by nardosinone.
External links
- Bucladesine at the US National Library of Medicine Medical Subject Headings (MeSH)
Phosphodiesterase inhibitors
|
|
PDE1 |
- MMPX
- SCH-51866
- Vinpocetine
|
|
PDE2 |
|
|
PDE3 |
- Amrinone
- Anagrelide
- Bucladesine
- Cilostamide
- Cilostazol
- Enoximone
- KMUP-1
- Milrinone
- Quazinone
- RPL-554
- Siguazodan
- Trequinsin
- Vesnarinone
- Zardaverine
|
|
PDE4 |
- Arofylline
- Atizoram
- Cilomilast
- Denbutylline
- Drotaverine
- Etazolate
- Filaminast
- Glaucine
- HT-0712
- Ibudilast
- ICI-63197
- Irsogladine
- Luteolin
- Mesembrine
- Piclamilast
- Roflumilast
- Rolipram
- Ro20-1724
- RPL-554
- YM-976
|
|
PDE5 |
- Acetildenafil
- Aildenafil
- Avanafil
- Dipyridamole
- Icariin
- Lodenafil
- Mirodenafil
- MY-5445
- Nitrosoprodenafil
- Sildenafil
- Sulfoaildenafil
- T-0156
- Tadalafil
- Udenafil
- Vardenafil
|
|
PDE6 |
|
|
PDE7 |
|
|
PDE9 |
|
|
PDE10 |
- Papaverine
- PF-2545920
- Tofisopam
|
|
PDE11 |
BC11-38
|
|
Nonselective |
- Caffeine
- Doxofylline
- IBMX
- Pentoxifylline
- Propentofylline
- Theophylline
|
|
Cardiac stimulants excluding cardiac glycosides (C01C)
|
|
Adrenergic and
dopaminergic agents |
Adrenergic agonists |
α |
- Metaraminol
- Phenylephrine
- Methoxamine
- Norfenefrine
- Oxedrine
- Midodrine
- Mephentermine
|
|
β |
- Dobutamine
- Arbutamine
- Isoprenaline
- Prenalterol
|
|
mixed |
- Amezinium metilsulfate
- Epinephrine #
- Norepinephrine
- Etilefrine
|
|
|
Dopamine agonists |
|
|
Both |
- Dopamine #
- Dopexamine
- Ibopamine
- Octopamine
|
|
Unknown/ungrouped |
- Dimetofrine
- Gepefrine
- Cafedrine
- Theodrenaline
|
|
|
Phosphodiesterase inhibitors (PDE3I) |
- Amrinone
- Milrinone
- Enoximone
- Bucladesine
|
|
Other cardiac stimulants |
- Angiotensinamide
- Xamoterol
- Levosimendan
- Pimobendan
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
noco/cong/tumr, sysi/epon, injr
|
proc, drug (C1A/1B/1C/1D), blte
|
|
|
|
English Journal
- Reduction of autophagy markers mediated protective effects of JNK inhibitor and bucladesine on memory deficit induced by Aβ in rats.
- Mohammadi M1, Guan J2,3,4, Khodagholi F5,6, Yans A5,6, Khalaj S1, Gholami M1, Taghizadeh GH1,7, Aliaghaei A8, Abdollahi M1, Ghahremani MH1, Sharifzadeh M9,10.
- Naunyn-Schmiedeberg's archives of pharmacology.Naunyn Schmiedebergs Arch Pharmacol.2016 Feb 22. [Epub ahead of print]
- Autophagy, the process of self-degradation of cellular components, has an important role in neurodegenerative diseases, such as Alzheimer's disease. In this study, we investigated the effects of SP600125 as c-Jun N-terminal kinase (JNK) inhibitor and bucladesine as a cyclic adenosine 3',5'-monophosp
- PMID 26899864
- Abdominal adipocyte populations in women with visceral obesity.
- Michaud A1, Laforest S1, Pelletier M2, Nadeau M2, Simard S2, Daris M2, Lebœuf M2, Vidal H2, Géloën A2, Tchernof A3.
- European journal of endocrinology / European Federation of Endocrine Societies.Eur J Endocrinol.2016 Feb;174(2):227-39. doi: 10.1530/EJE-15-0822. Epub 2015 Nov 17.
- BACKGROUND: Visceral obesity is independently related to numerous cardiometabolic alterations, with adipose tissue dysfunction as a central feature.OBJECTIVE: To examine whether omental (OM) and subcutaneous (SC) adipocyte size populations in women relate to visceral obesity, cardiometabolic risk fa
- PMID 26578637
- Organophosphate Flame Retardants act as Endocrine-Disrupting Chemicals in MA-10 Mouse Tumor Leydig Cells.
- Schang G1, Robaire B2, Hales BF1.
- Toxicological sciences : an official journal of the Society of Toxicology.Toxicol Sci.2016 Jan 21. pii: kfw012. [Epub ahead of print]
- The organophosphate flame retardants (OPFRs) have emerged as alternatives to banned brominated flame retardants but little is known about their possible activity as endocrine disruptors. Our goal was to compare the effects of seven commonly used OPFRs in vitro on MA-10 mouse Leydig tumor cells to th
- PMID 26794138
Japanese Journal
- Long-Term Exposure of RN46A Cells Expressing Serotonin Transporter (SERT) to a cAMP Analog Up-regulates SERT Activity and Is Accompanied by Neural Differentiation of the Cells
- Yammamoto Hikaru,Tanaka Shigeru,Tanaka Anna,Hide Izumi,Seki Takahiro,Sakai Norio
- Journal of Pharmacological Sciences, 2012
- … To examine the functional regulation of serotonin transporter (SERT) by cAMP, we examined whether SERT uptake activity was affected by dibutyryl cAMP (dbcAMP), a cAMP analog, in SERT-transfected RN46A cells derived from embryonic rat raphe neurons. … 4 h) of dbcAMP (1 mM) to SERT-expressing RN46A cells significantly up-regulated SERT activity. … Time-dependent up-regulation of SERT activity by dbcAMP was accompanied by neural differentiation of RN46A cells. …
- NAID 130002507905
- Effects of Preservation of Porcine Oocytes by Dibutyryl Cyclic AMP on in vitro Maturation, Fertilization and Development
- FUCHIMOTO Dai-ichiro,SENBON Shoichiro,SUZUKI Shunichi,ONISHI Akira
- Japan Agricultural Research Quarterly: JARQ 45(3), 295-300, 2011
- … In this study, the effects of dibutyryl cyclic AMP (dbcAMP) on the preservation of porcine oocytes were investigated. … Oocytes were preserved for 24 h or 48 h in modified NCSU37 supplemented with or without 1 mM dbcAMP. … After the preservation, 98.3% and 95.2% of oocytes incubated with dbcAMP for 24 h and 48 h, respectively, were at the germinal vesicle stage, whereas about a half of the oocytes incubated without dbcAMP underwent germinal vesicle break down. …
- NAID 130002147942
Related Links
- ChEMBL · CHEMBL485980 Yes Y. Synonyms, • Dibutyryl cyclic adenosine monophosphate • (N6,2'-O-dibutyryl)-adenosine-3',5'-mono-phosphate • Dibutyryl cAMP • DcAMP • DBcAMP. Chemical data. Formula · C18H23N5NaO8P · Mol. mass ...
- Recent studies have shown that N(6),2'-O-dibutyryladenosine 3':5' cyclic monophosphate (dbcAMP) increases the expression of specific subtypes of Na(+ )-dependent glutamate transporters in cultured astrocytes. Our group also found that ...
★リンクテーブル★
[★]
- 英
- bucladesine、
- 同
- ジブチリル環状AMP, ジブチリルcAMP, db-cAMP, dbcAMP, dibutyryl cyclic AMP
- 化
- ブクラデシンナトリウム bucladesine sodium
- 商
- アクトシン
- 関
- 強心剤
[★]
- 英
- dibutyryl cyclic AMP、bucladesine、db-cAMP、dbcAMP
- 関
- ブクラデシン、ジブチリルサイクリックAMP
[★]
- 関
- bucladesine、dbcAMP、dibutyryl cyclic AMP
[★]
ジブチリルサイクリックAMP、ジブチリル環状AMP
- 関
- bucladesine、db-cAMP、dbcAMP